Multiple sclerosis is a disease in which an individual’s own immune system attacks the fatty myelin sheath which is a protective layer that covers the nerve fibres, causing communication problems between the brain and rest of the body resulting into a permanent damage or deterioration and eventually death. Data shows that nearly 15% of the the people suffering from multiple sclerosis experience a subset of the disease known as primary-progressive multiple sclerosis which is characterised by gradual onset and steady progression of signs and symptoms. Recently U.S.Food and Drug Administration (FDA) approved therapeutic monoclonal antibody with a novel target as the first and only treatment for primary-progressive multiple sclerosis patients.
The FDA ruled on ofatumumab in August 2020. But the only FDA-approved medication for the struggling subset of multiple sclerosis with the primary-progressive condition is ocrelizumab making it the only drug for such patients for whom no treatment existed so far.